Couch J R, Ziegler D K, Hassanein R
Neurology. 1976 Feb;26(2):121-7. doi: 10.1212/wnl.26.2.121.
Amitriptyline was evaluated as a prophylactic antimigraine agent in 110 patients with severe migraine. This agent improved the migraine more than 50 percent in 72 percent of patients and more than 80 percent in 57 percent of patients. Most of the 31 patients with less than 50 percent improvement had virtually no response. Depression, measured with the Zung Self-Rating Depression Scale, was absent in 40 patients, borderline in 53, and moderate to severe in 17. Overall, depression ratings improved minimally with therapy. There was a weak relationship between improvement in depression and improvement in migraine. Subgroups with a stronger correlation of these could not be found. This work suggests that amitriptyline is effective in migraine prophylaxis and that it has a primary effect on migraine that is relatively independent of its antidepressant action.
在110例重度偏头痛患者中对阿米替林作为预防性抗偏头痛药物进行了评估。该药物使72%的患者偏头痛改善超过50%,57%的患者改善超过80%。31例改善不足50%的患者中,大多数几乎没有反应。用zung自评抑郁量表测量,40例患者无抑郁,53例为临界状态,17例为中度至重度。总体而言,治疗后抑郁评分改善甚微。抑郁改善与偏头痛改善之间存在微弱关系。未发现二者相关性更强的亚组。这项研究表明,阿米替林在预防偏头痛方面有效,且其对偏头痛的主要作用相对独立于其抗抑郁作用。